Stay updated on Miransertib in Overgrowth Spectrum Clinical Trial

Sign up to get notified when there's something new on the Miransertib in Overgrowth Spectrum Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Miransertib in Overgrowth Spectrum Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:53:20.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the Phase 1/2 study of ARQ 092 (Miransertib) in subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome.
    Difference
    0.1%
    Check dated 2024-06-06T14:52:31.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    45%
    Check dated 2024-05-22T21:37:56.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:32:50.000Z thumbnail image

Stay in the know with updates to Miransertib in Overgrowth Spectrum Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Miransertib in Overgrowth Spectrum Clinical Trial page.